0000009253 00000 n
17e édition (Révision) Médicaments essentiels Liste modèle de lʹOMS (mars 2011) Note explicatives La liste principale correspond aux besoins minimaux en médicaments d’un système de soins de santé de base et indique les médicaments qui ont la meilleure efficacité, la meilleure innocuité et le meilleur rapport Une commande exige de déterminer au préalable les besoins. Liste der Antigentests gem. Une liste de médicaments essentiels a été établie par le Ministère de la santé, visant à la prise en charge efficiente des pathologies les plus courantes : soigner le maximum de maladies (95%) avec le minimum de médicaments. 0000002629 00000 n
des médicaments, pour les patients souffrant de troubles psychiques et leur famille, pour les soignants. Les questions à la conférencière peuvent être … Liste des médicaments commercialisés valable au 1er octobre 2020 Cette liste se base sur des données qui sont de la compétence de la Direction de la Santé, Division de la Pharmacie et des Médicaments, du Ministère de la sécurité sociale et de la Caisse nationale de santé. 2 Ordonnance du DFI du 29 septembre 1995 sur les prestations dans l’assurance obligatoire des soins en cas de maladie (Ordonnance sur les prestations de l’assurance des soins, OPAS) Consultez directement les notices des médicaments en ligne pour connaitre leurs indications thérapeutiques, leurs contre-indications, leurs précautions d'emploi, leurs modalités d'administration (posologie), etc. Consultez le règlement pour l'officine publique (PDF, versi Powder for dilution in 200 mL, 500 mL, 1 L: Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged), Oral > Liquid: 12 mg per mL powder for oral liquid, Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate), Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial, Parenteral > General injections > unspecified: 10 IU per mL, Oral > Solid: 500 mg tablet; 4 g granules in sachet, Parenteral > General injections > IV: 6 mg per mL. En effet, le risque médicamenteux est majoré :20% des personnes âgées présentent un effet indésirable par an et 20% des effets indésirables surviennent chez les personnes âgées. 0000002962 00000 n
Dans leur charte, les professionnels du Réseau PIC s’engagent à répondre professionnellement à toutes les personnes souhaitant les interroger par courrier électronique … kétamine Solution injectable: 50 mg (sous forme de chlorhydrate)/ml, en flacon de 10 ml. La CNOPS, en tant qu'organisme gestionnaire, a conclu une convention nationale avec les pharmaciens d'officine pour la prise en charge d'une liste de 118 médicaments coûteux.Pour en bénéficier, les pharmaciens doit être accepté en mode tiers payant et un dossier de demande de prise en charge doit être introduit auprès des services de contrôle médical de la CNOPS April 2016 v.1 1 Prescriber ID Reference Code/Code de référence de l’ID du prescripteur Province. The current versions are the 21st WHO Essential Medicines List (EML) and the 7th WHO Essential Medicines List for Children (EMLc) updated in June 2019. WHO Electronic EML. But de la liste de médicaments du Programme des SSNA La liste des médicaments contient les médicaments couverts par le Programme des SSNA. Conférencière: Claire Hippert, Ph.D., Roche Innovation Center Basel. 1 Satz 1 TestV veröffentlicht Mehr. All vaccines should comply with the WHO requirements for biological substances. 0000002154 00000 n
startxref
0000001570 00000 n
Lorsque la présente liste limite la prescription de médicaments par la mention L, le médecin doit respecter cette limitation. 0000005185 00000 n
%PDF-1.4
%����
3 II. Liste des médicaments concernés Voici la liste des médicaments qui ne devraient plus être pris en charge par la Sécurité sociale, selon Le Parisien du mardi 13 septembre. 0000010501 00000 n
2011 . 0000004023 00000 n
Liste des médicaments Produits pharmaceutiques 13/01/2021 1/725. Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase. Cliquez sur le nom du médicament pour afficher plus de détails (Prix, Tarif de référence, DCI, Laboratoire,...etc). 0000004102 00000 n
DERMATOLOGIE BIOSTIM, crème ; CYSTINE B6 BAIL-LEUL cpr bt 20 ; DERMO-6 LOC sol fl200ml bt 1 ; LOBAMINE CYSTEINE gelu bt 20 et bt 60 ; OXYPEROL pâte tb50 g bt 1 ; … Liste des principes actifs des médicaments dont les Laboratoires Grünenthal sont exploitants des autorisations de mise sur le marché, en conformité avec l’Article L.5121-1-3 du Code de la Santé Publique Nom Commercial Dénomination Commune Internationale (DCI) LISTE DES FABRICANTS DE MÉDICAMENTS ET DES GROSSISTES EN MÉDICAMENTS Loi sur l'assurance médicaments - (L.R.Q., c. A-29.01, a.60) A) Fabricants reconnus par le ministre 3M Canada 3M Canada Inc. AA Pharma AA Pharma Inc. Abbott Laboratoires Abbott Ltée AbbVie La Corporation AbbVie Ab Diabete Abbott, Soins du diabète Laboratoires Abbott Accel Accel … Entrée libre. 0000000016 00000 n
24551 21
Contenu de la liste La LNME version 2010 comprend trois parties : • 1ère partie : les médicaments … - le portail dynamique et système de gestion de contenu. Comment puis-je participer à une étude clinique ? Scribd ist die weltweit größte soziale Plattform zum Lesen und Veröffentlichen. PDF Excel (XLSX) Word (DOCX) You can select particular sections to be included in the output file. Le médecin-chef et le responsable de la pharmacie doivent se référer à la liste des médicaments disponibles à la Centrale qui est issue de la liste nationale révisée des MEG. The WHO Model Lists of Essential Medicines has been updated every two years since 1977. Sprache : Französisch Pdf - 955 KB - 221 Seite(n) Herunterladen In anderen Sprachen. Medicines under additional monitoring have a black inverted triangle displayed in their package leaflet and summary of product characteristics , together with a short sentence explaining what the … 1. eine Liste der Analysen mit Tarif, 2. eine Liste der in der Rezeptur verwendeten Präparate, Wirk- und Hilfs-stoffe mit Tarif; dieser umfasst auch die Leistungen des Apothekers oder der Apothekerin, 3. x���1 01;T��\��S�. Found 1098 recommendations for 557 medicines and 44 therapeutic equivalents, Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified, Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteriodal anti-inflammatory drugs, Acute rheumatic fever without mention of heart involvement, Unspecified injury, poisoning or certain other consequences of external causes, Other specified malignant neoplasms of bronchus or lung, Acute myeloid leukaemia with recurrent genetic abnormalities, Inflammatory and other diseases of prostate (severe), Multi-drug resistant tuberculous Mycobacterium, Amodiaquine + sulfadoxine + pyrimethamine, Acute malnutrition in infants, children or adolescents (uncomplicated) [children], Acute malnutrition in infants, children or adolescents (complicated) [children], Bacterial pneumonia (Community-acquired pneumonia - mild to moderate), Chronic obstructive pulmonary disease with acute exacerbation, Bacterial pneumonia (Community-acquired pneumonia - severe) [children], Other specified pneumonia (Hospital-acquired pneumonia), Bacterial cellulitis, erysipelas and lymphangitis, Bacterial pneumonia (Community-acquired pneumonia - severe), Other specified malignant neoplasms of breast, Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified, Skeletal muscle relaxants [neuromuscular blocking agents], Exposure to or harmful effects of undetermined intent of pesticides, Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, Failure or rejection of transplanted organs or tissues, Gastroenteritis and colitis without specification of infectious agent, Need for immunization against tuberculosis, Chronic lymphocytic leukaemia or small lymphocytic lymphoma, Other specified malignant neoplasms of the ovary, Kaposi sarcoma of unspecified primary site, Malignant neoplasm metastasis in large intestine, Malignant trophoblastic neoplasms of placenta, Burkitt lymphoma including Burkitt leukaemia, Osteosarcoma of bone and articular cartilage of unspecified sites, Inflammatory and other diseases of prostate (mild to moderate), Pseudomonas aeruginosa resistant to other antibiotic, Carbapenem resistant Acinetobacter baumannii, Carbapenem-resistant Pseudomonas aeruginosa, Schizophrenia or other primary psychotic disorders, Need for immunization against cholera alone, Helicobacter pylori associated gastric ulcer, Female infertility without specification whether primary or secondary, Presence of coronary angioplasty implant or graft, Coagulation defects, purpura or other haemorrhagic or related conditions, Other specified disorders of fluid, electrolyte or acid-base balance, Contact with health services for contraceptive management, Contact with health services for insertion of contraceptive device, Ewing sarcoma of bone and articular cartilage of unspecified sites, Malignant neoplasms of kidney, except renal pelvis, Harmful effects of drugs, medicaments or biological substances, not elsewhere classified, Other specified sickle cell disorders or other haemoglobinopathies, Need for immunization against certain single viral diseases, Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy, Allergic or hypersensitivity conditions of unspecified type, Persistent hyperinsulinemic hypoglycaemia of infancy, Dihydroartemisinin + piperaquine phosphate, Need for immunization against diphtheria alone, Contact with or exposure to human immunodeficiency virus, Estradiol cypionate + medroxyprogesterone acetate, Contact with health services for reasons associated with reproduction, Ethambutol + isoniazid + pyrazinamide + rifampicin, Nutritional anaemias complicating pregnancy, childbirth and the puerperium, Blood transfusion without reported diagnosis, Hypoglycaemia without associated diabetes, Need for immunization against single bacterial diseases, Need for immunization against viral hepatitis, Megaloblastic anaemia due to vitamin B12 deficiency, Gastrointestinal stromal tumour of unspecified gastrointestinal sites, Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim, Contact with health services for postcoital contraception, Methicillin resistant Staphylococcus aureus, Vancomycin resistant Staphylococcus aureus, Need for immunization against measles alone, Excessive menstruation with irregular cycle, Osteosarcoma of bone and articular cartilage of other specified sites, Enterocolitis due to Clostridium difficile, Termination of pregnancy, affecting surviving fetus or newborn, Unspecified abortion, incomplete, without complication, Need for immunization against mumps alone, Unintentional exposure to or harmful effects of opioids or related analgesics, Influenza due to seasonal identified influenza virus, Schistosomiasis due to Schistosoma mansoni, Need for immunization against pertussis alone, Haemorrhagic disorder due to other specified circulating anticoagulants, Haemorrhagic or haematological disorders of foetus or newborn, Need for immunization against poliomyelitis, Other specified pyogenic bacterial infection of skin and subcutaneous tissue, Other specified congenital anomaly of great arteries including arterial duct, Viral haemorrhagic fever, not elsewhere classified, Need for immunization against rubella alone, Testicular dysfunction or testosterone-related disorders, Need for immunization against tetanus alone, Neonatal conjunctivitis or dacryocystitis, Need for immunization against arthropod-borne viral encephalitis, Need for immunization against typhoid-paratyphoid alone, Kaposi sarcoma of other specified primary sites, Other specified diseases of arteries or arterioles, Cerebral ischaemic stroke due to embolic occlusion, Unspecified appropriateness of dosing or administration without injury or harm, Malignant neoplasm metastasis in bone or bone marrow, Oral > Solid: 60 mg tablet (dispersible, scored) (as sulfate); 300 mg tablet (as sulfate), Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored), Local > Otological > drops: 2% in alcohol, Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule, Local > Rectal > Suppository: 50 to 150 mg, Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt), Local > Ophthalmological > Ointment: 3% w/w, Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL, Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol, Oral > Solid: 100 mg tablet; 300 mg tablet, Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection, Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt), Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate), Parenteral > General injections > unspecified: 1 g in vial powder for injection (as sulfate); 500 mg in vial powder for injection (as sulfate); 100 mg in vial powder for injection (as sulfate), Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride), Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride), Oral > Solid: 5 mg (as maleate, mesylate or besylate), Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride), Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package, Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid, Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate), Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection, Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection, Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid, Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt), Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex), Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection, Parenteral > General injections > IV: 250 µg in single-dose vial, Parenteral > General injections > IM: 250 µg in single-dose vial, Parenteral > General injections > IM: 150 IU per mL in vial, Parenteral > Locoregional injections > Other: 150 IU per mL in vial, Parenteral > General injections > IM: 500 IU in vial, Oral > Liquid: 125 mg powder for oral suspension (in sachet), Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion, Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection), Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet, Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution, Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules, Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet, Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet, Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules, Parenteral > General injections > unspecified: 10000 IU in vial powder for injection, Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate), Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable), Parenteral > General injections > IV: 10 mg per mL (besylate), Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate), Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate), Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt), Local > Ophthalmological > Solution (eye drops): 1.5% eye drops, Oral > Liquid: 200 mg per 5 mL oral liquid, Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule. Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae), Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL, Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU), Oral > Solid: 100 mg tablet; 50 mg tablet (scored); 12.5 mg tablet, Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt), Local > Topical > Cream: 0.1% (as valerate), Local > Topical > Ointment: 0.1% (as valerate), Parenteral > Locoregional injections > Intravitreal: 25 mg per mL, Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate), Oral > Solid: 2 mg tablet (hydrochloride), Parenteral > General injections > unspecified: 15 mg in vial (as sulfate), Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection, Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose, Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose, Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution, Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride), Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL), Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL), Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet, Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule, Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule, Oral > Solid: 150 mg tablet; 500 mg tablet, Oral > Solid: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable), Oral > Solid: 100 mg scored; 200 mg scored, Parenteral > General injections > IV: 100 µg per mL (heat stable), Parenteral > General injections > unspecified: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL, Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid, Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection, Oral > Liquid: 100 mg per 5 mL powder for oral liquid, Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate), Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt), Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection, Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection, Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt), Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection, Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate), Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection, Oral > Liquid: 150 mg per 5 mL (as palmitate), Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine), Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine), Local > Topical > Solution: 5% (digluconate) for dilution, Local > Topical > Powder: 0.1% available chlorine for solution, Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate), Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate), Oral > Solid: 150 mg tablet (as phosphate or sulfate), Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate), Oral > Liquid: 25 mg per 5 mL (hydrochloride), Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride), Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride), Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection, Local > Otological > drops: 0.3% (as hydrochloride), Parenteral > General injections > IV: 2 mg per mL (as hyclate), Oral > Liquid: 250 mg per 5 mL (anhydrous), Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL, Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid, Parenteral > General injections > unspecified: 500 mg in vial powder for injection, Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride), Oral > Solid: 150 mg (as hydrochloride) capsule, Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection, Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride), Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet, Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid, Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule, Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection, Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg, Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection, Parenteral > General injections > IV: 500 IU in vial powder for injection, Oral > Solid: 30 mg tablet (codeine phosphate), Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium), Parenteral > General injections > IV: injectable solution, Parenteral > General injections > unspecified: 50 mg per mL, Parenteral > General injections > IV: 500 mg in vial powder for injection, Oral > Solid: 25 mg tablet; 50 mg tablet, Parenteral > General injections > unspecified: 100 mg in vial powder for injection, Parenteral > General injections > IV: 100 mg in vial powder for injection, Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride), Parenteral > General injections > IV: 500 µg in vial powder for injection, Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet, Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg, Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet, Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection, Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate), Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate), Local > Nasal > Spray: 10 µg per dose (acetate), Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium)), Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt), Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt), Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL, Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg, Parenteral > General injections > IV: 6% injectable solution, Local > Rectal > Gel: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes, Local > Rectal > Solution: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes, Oral > Solid: 5 mg (scored); 2 mg (scored), Local > Rectal > Solution: 2.5 mg; 5 mg; 10 mg, Parenteral > General injections > unspecified: 5 mg per mL, Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate), Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule, Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet, Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule, Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial, Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL, Oral > Liquid: 50 mg per 5 mL oral liquid, Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil), Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride), Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride), Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous), Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate), Oral > Solid: 100 mg (hydrochloride or hyclate), Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate), Oral > Solid: 600 mg tablet; 200 mg scored tablet, Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil), Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil), Parenteral > General injections > IV: 200 mg per mL in 100 mL bottle (hydrochloride), Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil), Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate), Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule, Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule, Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride), Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride), Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride), Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate), Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate), Oral > Liquid: 250 µg per mL (10 000 IU per mL), Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate), Local > Ophthalmological > Ointment: 0.5%, Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe, Parenteral > General injections > IM: 5 mg + 25 mg, Oral > Solid: 100 to 400 mg tablet (hydrochloride); 100 mg dispersible tablet, Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet, Oral > Solid: 275 mg + 75 mg + 150 mg tablet, Local > Topical > Solution: 70% (denatured), Oral > Solid: 125 mg tablet; 250 mg tablet; 125 mg tablet (dispersible), Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule, Oral > Solid: 100 mg capsule; 50 mg capsule, Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour, Oral > Liquid: 25 mg per mL iron (as sulfate), Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial, Parenteral > General injections > IV: 2 mg per mL in vial, Parenteral > General injections > IV: 2.5 g per 250 mL infusion, Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection, Oral > Solid: 10 mg tablet (fludarabine phosphate), Local > Ophthalmological > Solution (eye drops): 1% (sodium salt), Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule, Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate), Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base), Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection, Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule, Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection, Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate), Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate), Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release, Parenteral > General injections > unspecified: 1 mg per mL, Parenteral > General injections > IV: 5% isotonic; 10% hypertonic, Parenteral > General injections > IV: 50% hypertonic, Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L), Parenteral > General injections > IM: 5 mg per mL in ampoule, Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule, Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule, Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride), Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride), Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate), Local > Rectal > Suppository: 25 mg (acetate), Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate), Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate), Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g, Parenteral > General injections > unspecified: 20 mg per mL injection, Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch, Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection, Parenteral > General injections > IV: 5 mg per mL, Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection, Oral > Solid: 100 mg tablet; 400 mg tablet, Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble), Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin, Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule, Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle, Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule, Respiratory > Inhalation > aerosol: 20 µg per dose, Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial, Oral > Solid: 100 to 300 mg tablet; 50 mg tablet (scored); 100 mg tablet (dispersible), Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible); 75 mg + 400 mg + 150 mg tablet, Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored), Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet, Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride), Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid, Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet, Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet, Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible), Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops, Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe, Oral > Solid: 50 mg tablet; 150 mg tablet (as hydrochloride), Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet, Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible).